News

Cynata Therapeutics will begin a preclinical study to investigate the mechanisms underlying the high potency of its cell therapy, Cymerus mesenchymal stem cells (MSCs), in treating lung diseases such as idiopathic pulmonary fibrosis (IPF). In an earlier study, the investigational therapy was able…

MYMD-1, MyMD Pharmaceuticals’ lead candidate for the treatment of several autoimmune and age-related disorders, showed promising efficacy in targeting the root causes of inflammation in idiopathic pulmonary fibrosis (IPF), according to data from a recent study. The therapy reduced the activity of molecules that are known drivers of…

For Rare Disease Day this Feb. 28, the Pulmonary Fibrosis Foundation (PFF) wants to raise public awareness of pulmonary fibrosis (PF), its symptoms and the importance of an early diagnosis. “The PFF is committed to providing quality disease education for the PF community,” Joyce S. Lee, senior medical advisor for…

Pretreatment with retinoic acid was found to stimulate the repair of damaged alveoli — the tiny air sacs in the lungs — in a mouse model of idiopathic pulmonary fibrosis (IPF) by upregulating a molecule called PDGFA. The researchers used an aged mouse model to simulate the lung…

Rare Disease Day at NIH, organized by the National Institutes of Health (NIH) and taking place on March 1, will feature panel discussions, patient stories, research updates, TED-style talks, and a presentation by a Nobel laureate recently recognized for her work on a gene editing tool. The free, virtual…

The University of South Florida (USF) received a $1 million donation to fund research focused on finding ways to detect and prevent lung tissue scarring in people with pulmonary fibrosis (PF). “This generous gift will help the University of South Florida advance innovative testing and treatment of the toughest…

People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare disease patients overall give their healthcare experience a medium-low rating, of 2.5 on a scale of 1 to 5,…